Vienna General Hospital

EQS-News: STRABAG expands service portfolio in technical facility management with acquisition of parts of VAMED

Retrieved on: 
Friday, May 10, 2024
Construction, Investment, Climate, PAI Partners, Environment, Supervisory board, STRABAG, Acquisition, Vienna General Hospital

The acquisition expands STRABAG’s service portfolio in technical facility management to include the highly demanding medical sector while enhancing its expertise in project development in the healthcare sector.

Key Points: 
  • The acquisition expands STRABAG’s service portfolio in technical facility management to include the highly demanding medical sector while enhancing its expertise in project development in the healthcare sector.
  • The acquisition comprises the following parts of the VAMED Group:
    The seller of these holdings is VAMED AG, which is majority-owned by Fresenius SE & Co. KGaA of Germany.
  • The acquisition is to be realised via a joint holding company, with PORR AG and STRABAG SE holding a 50% stake each.
  • The service portfolio includes technical and infrastructure facility management, property management, building technology and specialised industrial services.

Implantica publishes Interim Report January - September 2023 (Q3)

Retrieved on: 
Wednesday, November 22, 2023
ID, Mary, mother of Jesus, Corporate Affairs, Safety, Food, CFO, Saint Mary's Hospital, GERD, Investment, EFS, Surgeon, Nissen fundoplication, Learning, Vienna General Hospital, Patient, CET, Congress, FDA, ARB, NHS, AFS, Food and Drug Administration, Usability, IPAC, Certification, ISPOR, Health, Hospital, PMA, Hernia, Pharmaceutical industry, Medical device

The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.

Key Points: 
  • The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.
  • The IPAC review process is a key step for NHS hospitals to adopt our technology with strong international influence.
  • Implantica will hold a teleconference on 22 November 2023 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer).
  • The information was submitted for publication, through the agency of the contact person set out above, at 2023-11-22 08:00 CET.

Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officer

Retrieved on: 
Tuesday, December 6, 2022
Technology, Research, Clinical Trials, Health Technology, Cardiology, Radiology, Health, Science, Artificial Intelligence, NIH, American Medical Association, Indian Medical Association, Framingham Heart Study, Harvard School of Dental Medicine, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, CT, II, Vienna, Radiology, Paulinum (University of Leipzig), Cancer, FACC, The New England Journal of Medicine, Cardiovascular disease, MGH, Intelligence, Division, Public, FDA, Coronary artery disease, MPH, Massachusetts General Hospital, Journal, Scan (company), Public health, Degenerative disease, Vienna General Hospital, University, FESC, National Institutes of Health, Lancet, Hospital, Principal, Harvard Medical School, Infarction, Health literacy, Medical imaging, Medical device, MD

Cleerly , the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer.

Key Points: 
  • Cleerly , the company creating a new standard of care for heart disease, announced it has appointed Udo Hoffmann, MD, MPH, as chief scientific officer.
  • Its with great enthusiasm that we welcome Dr. Hoffmann to Cleerly, said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly.
  • Udo has dedicated his professional career to the performance of landmark clinical trials that have fundamentally informed the clinical use of cardiovascular computed tomography (CT), and his scientific abilities are unparalleled.
  • Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway.

Isarna Therapeutics Appoints Claus Schalper as CEO

Retrieved on: 
Thursday, September 30, 2021
Health, Other Science, Research, Science, Pharmaceutical, Optical, Biotechnology, Biochemistry, Retina, Siberian State Medical University, Therapy, Clinical trial, Neoplasm, Anticalin, RNA transfection, XL, RNA, Novartis, Uveitis, Business administration, Feinberg School of Medicine, Bayer, TGF, Cancer, Arthur Andersen, AMD, Patient, Berlin, Board of directors, University of Bamberg, MD, Diabetic retinopathy, Warwick Business School, RTÉ Executive Board, Biology, NASH, CEO, University, CMO, Master of Business Administration, FEBO, Ophthalmology, Leadership, Gold, Medical school, MBA, Research, Drug development, DME, Safety, Fibrosis, Macular edema, Doctor of Philosophy, Eye, Vienna General Hospital, Management, Pharmaceutical industry

Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer.

Key Points: 
  • Isarna Therapeutics today announced the appointment of Claus Schalper as Chief Executive Officer.
  • Mr. Schalper joins Isarna with over 20 years of experience as an executive and serial entrepreneur in the life science and biotech industries.
  • Isarna has reached an exciting stage of development for its lead program, ISTH0036, which has broad applicability in a range of ophthalmology indications, said Claus Schalper, CEO of Isarna Therapeutics.
  • Mr. Schalper began his career with Arthur Andersen and subsequently served as CEO for several companies in the technology industry.